Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma

December 3rd 2018

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

Mosunetuzumab Shows Promise for Non-Hodgkin Lymphoma

December 3rd 2018

The CD3 and CD20 bispecific antibody mosunetuzumab demonstrated promising complete remission rates with tolerable toxicity for patients with relapsed/refractory B-cell indolent and aggressive non-Hodgkin lymphoma.

Ibrutinib Efficacy Sustained at 7-Year Analysis for CLL

December 3rd 2018

Single-agent ibrutinib continued to demonstrate strong results after 7 years of follow-up in both the frontline and heavily pretreated, relapsed/refractory setting for patients with CLL and SLL.

Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up

December 2nd 2018

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL

December 2nd 2018

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Personalized Immunotherapy Combinations on Horizon

November 9th 2018

Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.

CAR T-Cell Therapies Moving to Outpatient Setting

November 8th 2018

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

FDA Approves Moxetumomab Pasudotox for Hairy Cell Leukemia

September 13th 2018

The FDA has approved moxetumomab pasudotox for the treatment of adult patients with relapsed or refractory hairy cell leukemia following at least 2 prior lines of therapy.

FDA Delays Decision on Frontline Atezolizumab for NSCLC

September 6th 2018

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

FDA Grants LOXO-292 Breakthrough Designation for NSCLC, MTC

September 5th 2018

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer or RET-mutant medullary thyroid cancer.

Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC

July 29th 2018

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

Targeted Therapies on Horizon for RET-Rearranged NSCLC

July 29th 2018

RET is set to join the list of ever-expanding actionable driver mutations for non–small cell lung cancer, as there are now 3 highly effective therapies in development.

Immunotherapy Combos Rapidly Evolving for Lung Cancer

July 28th 2018

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Targeted Therapy Options Expanding for NSCLC

July 27th 2018

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Oncolytic Poliovirus Shows Sustained Survival Rates for Recurrent GBM

June 26th 2018

Treatment with the recombinant oncolytic poliovirus PVSRIPO elicited sustained a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.

Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study

June 25th 2018

The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.

Atezolizumab Combo Not Superior to Regorafenib for mCRC

June 22nd 2018

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels

June 21st 2018

The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.

Ramucirumab Extends Survival for AFP-Elevated HCC in Pooled Analysis

June 20th 2018

Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.